AMTI News and Press, Applied Molecular Transport Inc. From 03/29/21

Applied Molecular Transport (AMTI)  commenced an underwritten public offering of 2.5M shares; underwriters granted 30-day option to purchase up to an additional 375K shares.Offer size, terms not yet disclosed. For further details see: Applied Molecular Transport proposes 2.5M ...

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares...

Applied Molecular Transport (AMTI): FY GAAP EPS of -$2.91 beats by $0.38.As of December 31, 2020, cash, cash equivalents, and investments were $129.9 million.Press Release For further details see: Applied Molecular Transport EPS beats by $0.38

Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program, in multiple ulcerative colitis populations and rheum...

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during th...

Applied Molecular Transport (AMTI) announces that the first patient has been dosed in its Phase 1a clinical trial of oral AMT-126, a novel, gastrointestinal ((GI))-selective oral fusion of human interleukin-22 ((hIL-22)).The company expects complete data from its oral AMT-126 Phase 1a/b ...

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ul...

The following slide deck was published by Applied Molecular Transport Inc. in conjunction with this event. For further details see: Applied Molecular Transport (AMTI) Investor Presentation - Slideshow

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the...

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership re...